NCT06749860 is a Phase 2 clinical trial of Disitamab Vedotin + tislelizumab + bevacizumab in Lung Cancer, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT06749860?

NCT06749860 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT06749860?

Interventions in NCT06749860: Disitamab Vedotin + tislelizumab + bevacizumab.

What condition does NCT06749860 study?

NCT06749860 studies Lung Cancer.

Is NCT06749860 still recruiting?

NCT06749860 is currently recruiting now. Last updated 27 December 2024.

Last reviewed 2024-12-27 · How we verify

NCT06749860

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Recruiting now Phase 2 Last updated 27 December 2024

What this trial tests

Phase 2 trial testing Disitamab Vedotin + tislelizumab + bevacizumab in Lung Cancer in 58 participants. Currently enrolling.

Timeline

2 February 2024

Primary endpoint
6 June 2026

6 June 2027

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	2 February 2024
Primary completion	6 June 2026
Estimated completion	6 June 2027
Sites	1 location across China

Drugs / interventions tested

Disitamab Vedotin + tislelizumab + bevacizumab — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2 mutation/amplification/expression. The main questions it aims to answer are: 1. objective response rate; 2. Progression-Free Survival; 3. Overall Survival; 4. Disease Control Rate; 5. Duration of Response.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.
Debieuvre D, Macouillard P, Quantin X, Berktas M, et al · · 2026 · PMID 42252502 · DOI 10.1002/cam4.71975
Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.
Goto K, Hayashi H, Maruti SS, Zettl H, et al · · 2026 · PMID 42090048 · DOI 10.1007/s11523-026-01213-4
Evolving treatment strategies for HER2-altered non-small-cell lung cancer: the rise of TKIs and ADCs.
Balli S, Basoglu T, Ozdogan M. · · 2026 · PMID 41959903 · DOI 10.3389/fonc.2026.1771869

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06749860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 27 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing